These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 19671425)

  • 1. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
    Truffinet P; Bordet R; Ménard J
    Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scales as outcome measures for Alzheimer's disease.
    Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
    Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
    Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
    Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease.
    Doody RS
    Alzheimers Dement; 2009 Mar; 5(2):133-6. PubMed ID: 19328443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying approaches to Alzheimer's disease: challenges and opportunities-Lessons from donepezil therapy.
    Sabbagh MN; Richardson S; Relkin N
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S109-18. PubMed ID: 18631986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design issues in clinical trials.
    Overall JE
    Prog Clin Biol Res; 1989; 317():1291-9. PubMed ID: 2690096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clinical trials in Alzheimer's disease: selection and evaluation of drug candidates.
    Reines SA
    Prog Clin Biol Res; 1989; 317():1283-90. PubMed ID: 2690095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Memory: therapeutic approach. Clinical evaluation].
    Pasquier F
    Therapie; 2000; 55(4):513-9. PubMed ID: 11098729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical trials in the Alzheimer's disease: evaluation of the therapeutic response].
    Frank A; Barreiro P; Díez-Tejedor E
    Rev Neurol; 1995; 23(119):111-7. PubMed ID: 8548603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course.
    Schenk D
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S119-21. PubMed ID: 18631987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention trials in Alzheimer's disease: an EU-US task force report.
    Vellas B; Aisen PS; Sampaio C; Carrillo M; Scheltens P; Scherrer B; Frisoni GB; Weiner M; Schneider L; Gauthier S; Gispen-de Wied CC; Hendrix S; Feldman H; Cedarbaum J; Petersen R; Siemers E; Andrieu S; Prvulovic D; Touchon J; Hampel H
    Prog Neurobiol; 2011 Dec; 95(4):594-600. PubMed ID: 21925234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements.
    Broich K; Weiergräber M; Hampel H
    Prog Neurobiol; 2011 Dec; 95(4):498-500. PubMed ID: 21945642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Innovations in care that advance Alzheimer's disease drug development.
    Foster NL; Andersen TC; Zamrini EY
    Alzheimers Dement; 2009 Mar; 5(2):159-62. PubMed ID: 19328451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
    Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease.
    Lovestone S; Francis P; Kloszewska I; Mecocci P; Simmons A; Soininen H; Spenger C; Tsolaki M; Vellas B; Wahlund LO; Ward M;
    Ann N Y Acad Sci; 2009 Oct; 1180():36-46. PubMed ID: 19906259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic trials in Alzheimer disease. Selection--recruitment and stratification].
    Chaumet-Riffaud P; Wolmark Y; Péré JJ; Goulley F
    Therapie; 1993; 48(3):201-5. PubMed ID: 8140558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.